Literature DB >> 2536978

Conserved structural domains in the 5'-untranslated region of picornaviral genomes: an analysis of the segment controlling translation and neurovirulence.

E V Pilipenko1, V M Blinov, L I Romanova, A N Sinyakov, S V Maslova, V I Agol.   

Abstract

A model of secondary structure common for the central part (ca. 400 nucleotides) of the 5'-untranslated regions (5'-UTR) of all the so far sequenced genomes of polioviruses, coxsackieviruses, and rhinoviruses was derived on the basis of evolutionary and thermodynamic considerations. According to the model, this part of the genome comprises three domains, which appear to be involved, at least in the poliovirus genome, in the control of viral neurovirulence and in vitro translation. Some salient features of this model were supported by investigating RNAs of five poliovirus and one coxsackievirus strains with respect to their accessibility to modifications with dimethyl sulfate and sensitivity to single-strand- and double-strand-specific nucleases. In contrast to the previous suggestion, no major changes in the conformation of the Sabin vaccine poliovirus type 3 5'-UTR due to the transition in position 472 were observed. The biological relevance of the conserved primary and secondary structure elements in the picornaviral 5'-UTRs is discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536978     DOI: 10.1016/0042-6822(89)90259-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  117 in total

1.  Interactions of viral protein 3CD and poly(rC) binding protein with the 5' untranslated region of the poliovirus genome.

Authors:  A V Gamarnik; R Andino
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

2.  Cross-talk between orientation-dependent recognition determinants of a complex control RNA element, the enterovirus oriR.

Authors:  W J Melchers; J M Bakkers; H J Bruins Slot; J M Galama; V I Agol; E V Pilipenko
Journal:  RNA       Date:  2000-07       Impact factor: 4.942

3.  Conserved RNA secondary structures in Picornaviridae genomes.

Authors:  C Witwer; S Rauscher; I L Hofacker; P F Stadler
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

4.  Determination of the structure of a decay accelerating factor-binding clinical isolate of echovirus 11 allows mapping of mutants with altered receptor requirements for infection.

Authors:  Amanda D Stuart; Thomas A McKee; Pamela A Williams; Chris Harley; Shuo Shen; David I Stuart; T David K Brown; Susan M Lea
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

5.  A poliovirus replicon containing the chloramphenicol acetyltransferase gene can be used to study the replication and encapsidation of poliovirus RNA.

Authors:  N Percy; W S Barclay; M Sullivan; J W Almond
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

6.  Linker scanning mutagenesis of the internal ribosome entry site of poliovirus RNA.

Authors:  A A Haller; B L Semler
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

7.  Cap-independent translation by the 5' untranslated region of Theiler's murine encephalomyelitis virus.

Authors:  P K Bandyopadhyay; C Wang; H L Lipton
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

8.  Towards identification of cis-acting elements involved in the replication of enterovirus and rhinovirus RNAs: a proposal for the existence of tRNA-like terminal structures.

Authors:  E V Pilipenko; S V Maslova; A N Sinyakov; V I Agol
Journal:  Nucleic Acids Res       Date:  1992-04-11       Impact factor: 16.971

9.  Specific interactions of HeLa cell proteins with proposed translation domains of the poliovirus 5' noncoding region.

Authors:  J R Gebhard; E Ehrenfeld
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103

10.  Cell proteins bind to a linear polypyrimidine-rich sequence within the 5'-untranslated region of rhinovirus 14 RNA.

Authors:  I A Rojas-Eisenring; M Cajero-Juarez; R M del Angel
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.